The Transcription Factor FRA-1/AP-1 Controls Lipocalin-2 Expression and Inflammation in Sepsis Model.
Animals
Cytokines
/ metabolism
Endotoxin Tolerance
/ physiology
Female
Humans
Inflammation
/ genetics
Leukocytes, Mononuclear
/ metabolism
Lipocalin-2
/ metabolism
Lipopolysaccharides
/ metabolism
Macrophages
/ metabolism
Male
Mice
Mice, Inbred C57BL
Promoter Regions, Genetic
/ genetics
Proto-Oncogene Proteins c-fos
/ metabolism
Sepsis
/ genetics
Transcription Factor AP-1
/ metabolism
AP-1/Fra-1
endotoxin tolerance
lipocalin-2
macrophage
sepsis
transcription factor
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
28
04
2021
accepted:
24
09
2021
entrez:
29
10
2021
pubmed:
30
10
2021
medline:
22
12
2021
Statut:
epublish
Résumé
Sepsis is a life-threatening condition characterized by excessive inflammation in its early phase. This is followed by an aberrant resolution phase associated to a prolonged period of immune suppression that can ultimately lead to multiple organ dysfunctions. This immunosuppression can be mediated by the functional reprogramming of gene transcription in monocytes/macrophages in response to prolonged lipopolysaccharide (LPS) exposure. Surprisingly, there is no report on the role of AP-1 transcription factors in this reprogramming process. Herein, we used the endotoxin tolerance model on murine bone marrow-derived macrophages in which tolerant cells stimulated twice with LPS were compared to naïve cells stimulated once. Out of all AP-1 transcription factors tested,
Identifiants
pubmed: 34712224
doi: 10.3389/fimmu.2021.701675
pmc: PMC8546226
doi:
Substances chimiques
Cytokines
0
LCN2 protein, human
0
Lipocalin-2
0
Lipopolysaccharides
0
Proto-Oncogene Proteins c-fos
0
Transcription Factor AP-1
0
fos-related antigen 1
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
701675Informations de copyright
Copyright © 2021 Cao, Schnelzer, Hannemann, Schett, Soulat and Bozec.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Lancet Infect Dis. 2013 Mar;13(3):260-8
pubmed: 23427891
Am J Respir Cell Mol Biol. 1999 May;20(5):924-34
pubmed: 10226062
PLoS One. 2012;7(8):e42152
pubmed: 22879913
Nat Rev Nephrol. 2018 Feb;14(2):121-137
pubmed: 29225343
Front Immunol. 2017 May 08;8:493
pubmed: 28533774
J Immunol. 2012 Aug 15;189(4):1911-9
pubmed: 22786765
J Biol Chem. 2014 Feb 28;289(9):5960-9
pubmed: 24391115
Oncogene. 2005 Feb 17;24(8):1434-44
pubmed: 15608675
J Clin Invest. 2016 Aug 1;126(8):3089-103
pubmed: 27427981
Int Immunol. 2009 Apr;21(4):457-65
pubmed: 19251936
Nature. 2007 Jun 21;447(7147):972-8
pubmed: 17538624
Bioinformatics. 1999 Jul-Aug;15(7-8):622-30
pubmed: 10487870
J Clin Invest. 2019 Apr 16;129(7):2669-2684
pubmed: 30990796
Nat Rev Immunol. 2013 Dec;13(12):862-74
pubmed: 24232462
Bioinformatics. 2016 Jul 15;32(14):2089-95
pubmed: 27153568
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
Nucleic Acids Res. 2018 Jul 2;46(W1):W537-W544
pubmed: 29790989
Arthritis Res Ther. 2008;10(1):201
pubmed: 18226189
Cell Host Microbe. 2016 Apr 13;19(4):455-69
pubmed: 27078067
Methods Mol Biol. 2009;531:203-24
pubmed: 19347320
Am J Respir Cell Mol Biol. 2016 Nov;55(5):667-674
pubmed: 27286066
J Cell Sci. 2004 Dec 1;117(Pt 25):5965-73
pubmed: 15564374
Nat Med. 2000 Sep;6(9):980-4
pubmed: 10973316
EMBO Mol Med. 2020 Apr 7;12(4):e10128
pubmed: 32176432
J Clin Invest. 2013 Aug;123(8):3363-72
pubmed: 23863624
Arterioscler Thromb Vasc Biol. 2019 Nov;39(11):2353-2366
pubmed: 31644352
Crit Care Med. 2002 Jan;30(1 Suppl):S64-73
pubmed: 11782563
Immunity. 2015 Mar 17;42(3):484-98
pubmed: 25746953
Innate Immun. 2015 Jul;21(5):477-89
pubmed: 25227123
Cell Res. 2010 Jun;20(6):701-12
pubmed: 20386569
Sci Signal. 2016 Jun 28;9(434):ra64
pubmed: 27353364